Bukwang Pharm

Price Chart

Risk-Adjusted Performance

Bukwang Pharm (003000) Price Performance

Bukwang Pharm (003000) trades on KO in KRW. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at KRW7660.00, up 6.83% from the previous close.

Over the past year, 003000 has traded between a low of KRW3181.30 and a high of KRW9600.00. The stock has gained 111.7% over this period. It is currently 20.2% below its 52-week high.

Bukwang Pharm has a market capitalization of $709.40B, with a price-to-earnings ratio of 56.49 and a dividend yield of 1.69%.

About Bukwang Pharm

Bukwang Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products in South Korea and internationally. It offers its products in oral solid dosage forms, injections, oral solutions, external solutions, and ointments. The company also provides ethical drugs, including drugs for treating diabetic peripheral neuropathy, hypothyroidism, toxic liver disease, chronic hepatitis, liver cirrhosis, and iron-deficiency anemia; over-the-counter drugs, such as fever and pain relief medication, gastrointestinal medication, cold medication, laxatives for constipation, collagen supplements, multivitamin supplements, mouthwash, topical gels, oral health supplements, and omega-3 supplements; and personal products comprising toothpastes, toothbrushes, and other oral care products; nutraceuticals; health functional foods; and quasi drugs. In addition, it offers products for various threptic areas, including endocrinology, gastroenterology, cardiology, oncology, central nervous system, iron supplements, neuropsychiatry, respiratory/allergy, dermatology, urology, and other treatment areas. Further, the company's development pipeline comprises Lurasidone for the treatment of schizophrenia and bipolar depression; JM-010, for treating dyskinesia in parkinson's disease; SOL-804, which is used for the treatment of metastatic castration resistant prostate cancer; AhR Inhibitor for solid tumors; PKR Inhibitor for neurodegenerative disorders; and PD Program for parkinson's disease. Bukwang Pharmaceutical Co., Ltd. was founded in 1960 and is headquartered in Seoul, South Korea.

Compare Bukwang Pharm

Side-by-side comparison against top Healthcare peers.